Downregulation of ARFGEF1 and CAMK2B by promoter hypermethylation in breast cancer cells
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
To identify novel genes that are regulated by promoter methylation,a combinational approach involving in silico mining followed by molecular assay was performed. From the expression microarray data registered in the European bioinformatics institute (EBI), genes showing downregulation in breast cancer cells were initially screened and then selected by e-Northern analysis using the Unigene database. A series of these in silico methods identified CAMK2B and ARFGEF1 as candidates, and the two genes were revealed to be hypermethylated in breast cancer cell lines and hypomethylated in normal breast cell lines. Additionally, cancer cell lines showed downregulated expression of these genes. Furthermore, treatment of the cancer cell lines with a demethylation agent, 5-Aza-2’-deoxycytidine,recovered expression of CAMK2B and ARFGEF1, implying that hypermethyaltion silenced gene activity in cancer cells. Taken together, promoter methylations of CAMK2B and ARFGEF1 are novel epigenetic markers identified in breast cancer cell lines and can be utilized for the application to clinical cancer tissues. [BMB reports 2011; 44(8): 523-528]
Abstract
To identify novel genes that are regulated by promoter methylation,a combinational approach involving in silico mining followed by molecular assay was performed. From the expression microarray data registered in the European bioinformatics institute (EBI), genes showing downregulation in breast cancer cells were initially screened and then selected by e-Northern analysis using the Unigene database. A series of these in silico methods identified CAMK2B and ARFGEF1 as candidates, and the two genes were revealed to be hypermethylated in breast cancer cell lines and hypomethylated in normal breast cell lines. Additionally, cancer cell lines showed downregulated expression of these genes. Furthermore, treatment of the cancer cell lines with a demethylation agent, 5-Aza-2’-deoxycytidine,recovered expression of CAMK2B and ARFGEF1, implying that hypermethyaltion silenced gene activity in cancer cells. Taken together, promoter methylations of CAMK2B and ARFGEF1 are novel epigenetic markers identified in breast cancer cell lines and can be utilized for the application to clinical cancer tissues. [BMB reports 2011; 44(8): 523-528]
참고문헌 (20)
- Kulis, M, "DNA methylation and cancer", Adv. Genet, 70, pp.27~56 (2010)
- Dworkin, A. M, "Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment", Semin. Cancer Biol, 19, pp.165~171 (2009)
- Ai, L, "Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression", Cancer Res, 66, pp.7899~7909 (2006)
- Nabilsi, N. H, "DNA methylation inhibits p53-mediated survivin repression", Oncogene, 28, pp.2046~2050 (2009)
- Singh, P, "Overexpression and hypomethylation of flap endonuclease 1 gene in breast and other cancers", Mol. Cancer Res, 6, pp.1710~1717 (2008)
- Ito, Y, "Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer", Hum. Mol. Genet, 17, pp.2633~2643 (2008)
- Tommasi, S, "Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer", Breast Cancer Res, 11, pp.R14~ (2009)
- Van der Auwera, I, "Array-based DNA methylation profiling for breast cancer subtype discrimination", PLoS One, 5, pp.e12616~ (2010)
- Zeller, C, "SASH1: a candidate tumor suppressor gene on chromosome 6q24.3 is downregulated in breast cancer", Oncogene, 22, pp.2972~2983 (2003)
- Hesson, L, "NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers", Oncogene, 22, pp.947~954 (2003)
- Thirlwell, C, "Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue using the Illumina Infinium HumanMethylation27 BeadChip", Methods, 52, pp.248~254 (2010)
- Novak, G, "Increased expression of calcium", calmodulin-dependent protein kinase IIbeta in frontal cortex in schizophrenia and depression, 2006, pp.59, 61~68
- Pacheco-Rodriguez, G, "BIG1 and BIG2: brefeldin A-inhibited guanine nucleotideexchange proteins for ADP-ribosylation factors", Methods Enzymol, 345, pp.397~404 (2002)
- Teschendorff, A. E, "An epigenetic signature in peripheral blood predicts active ovarian cancer", PLoS One, 4, pp.e8274~ (2009)
- Padilla, P. I, "Association of guanine nucleotide-exchange protein BIG1 in HepG2 cell nuclei with nucleolin, U3 snoRNA, and fibrillarin", Proc. Natl. Acad. Sci. U. S. A, 105, pp.3357~3361 (2008)
- Pfeffer, S. R, "GTP-binding proteins in intracellular transport", Trends Cell Biol, 2, pp.41~46 (1992)
- Gaertner, T. R, "Comparative analyses of the three-dimensional structures and enzymatic properties of alpha, beta, gamma and delta isoforms of Ca2+-calmodulin-dependent protein kinase II", J. Biol. Chem, 279, pp.12484~12494 (2004)
- Takeuchi, Y, "Differential subcellular distribution of Ca2+", calmodulin-dependent protein kinase II isoforms in the striatum and NG108-15 cells, 2004, pp.75, 480~490
- Luedi, P. P, "Computational and experimental identification of novel human imprinted genes", Genome Res, 17, pp.1723~1730 (2007)
- Lu, L, "Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis", Cancer Res, 67, pp.10117~10122 (2007)